AIMS: To examine the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in invasive breast carcinoma in relation to known clinicopathological features, ERbeta, and relapse-free and overall patient survival. PPARgamma is a ligand-activated transcriptional factor that regulates the transcription of various target genes and has been implicated in human breast cancer. METHODS AND RESULTS: We performed immunohistochemistry to detect PPARgamma, ERalpha, PR and ERbeta in 170 infiltrative breast carcinomas. The results were subjected to statistical analysis. PPARgamma was detected in the cytoplasm of 58% of breast carcinoma samples. PPARgamma did not differ with regard to any of the clinicopathological parameters except for histological grade, to which it was found to be inversely correlated (P = 0.019), and ERbeta, to which it was positively related (P = 0.016). As regards relapse-free survival, in univariate statistical analysis PPARgamma was found to exert a marginally favourable impact on all the patients (P = 0.076), but a strong one on patients with ductal carcinoma (P = 0.027), whereas Cox's regression analysis depicted PPARgamma to be an independent prognosticator for patients with ductal carcinoma (P = 0.039). No association was found between PPARgamma expression and overall survival. CONCLUSION: These results indicate the favourable impact of PPARgamma expression on disease-free survival of patients with ductal breast carcinoma and its possible cooperation with ERbeta in exerting that favourable effect.
AIMS: To examine the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in invasive breast carcinoma in relation to known clinicopathological features, ERbeta, and relapse-free and overall patient survival. PPARgamma is a ligand-activated transcriptional factor that regulates the transcription of various target genes and has been implicated in humanbreast cancer. METHODS AND RESULTS: We performed immunohistochemistry to detect PPARgamma, ERalpha, PR and ERbeta in 170 infiltrative breast carcinomas. The results were subjected to statistical analysis. PPARgamma was detected in the cytoplasm of 58% of breast carcinoma samples. PPARgamma did not differ with regard to any of the clinicopathological parameters except for histological grade, to which it was found to be inversely correlated (P = 0.019), and ERbeta, to which it was positively related (P = 0.016). As regards relapse-free survival, in univariate statistical analysis PPARgamma was found to exert a marginally favourable impact on all the patients (P = 0.076), but a strong one on patients with ductal carcinoma (P = 0.027), whereas Cox's regression analysis depicted PPARgamma to be an independent prognosticator for patients with ductal carcinoma (P = 0.039). No association was found between PPARgamma expression and overall survival. CONCLUSION: These results indicate the favourable impact of PPARgamma expression on disease-free survival of patients with ductal breast carcinoma and its possible cooperation with ERbeta in exerting that favourable effect.
Authors: Cameron N Johnstone; Perry S Mongroo; A Sophie Rich; Michael Schupp; Mark J Bowser; Andrew S Delemos; John W Tobias; Yingqiu Liu; Gregory E Hannigan; Anil K Rustgi Journal: Mol Cell Biol Date: 2007-11-12 Impact factor: 4.272
Authors: Stamatios Theocharis; Jerzy Klijanienko; Constantinos Giaginis; Jose Rodriguez; Thomas Jouffroy; Angelique Girod; Daniel Point; Gerasimos Tsourouflis; Xavier Satre-Garau Journal: J Cancer Res Clin Oncol Date: 2011-02 Impact factor: 4.553
Authors: George E O Muscat; Natalie A Eriksson; Karen Byth; Sherene Loi; Dinny Graham; Shalini Jindal; Melissa J Davis; Colin Clyne; John W Funder; Evan R Simpson; Mark A Ragan; Elizabeth Kuczek; Peter J Fuller; Wayne D Tilley; Peter J Leedman; Christine L Clarke Journal: Mol Endocrinol Date: 2013-01-04
Authors: Martina C Herwig; Chris Bergstrom; Jill R Wells; Tobias Höller; Hans E Grossniklaus Journal: Exp Eye Res Date: 2012-11-30 Impact factor: 3.467